Omnicell Inc Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All righty. Welcome, everybody. My name is Stan Berenshteyn. I cover healthcare technology at Wells Fargo. With me today is Nnamdi Njoku, he is the President and COO, and Baird Radford, he is the CFO. Baird, did you want to maybe give us a quick preamble before we begin?
Yeah. Thanks, Stan, definitely for inviting us. We are excited to be here at the conference. Really appreciate the invite. Also, during the course of this presentation, we will make various statements that may be forward-looking. We encourage everybody to go to our public filings, the SEC filings on EDGAR, and take a look at the disclosures in their entirety. With that, turn it over.
Awesome. Well, maybe we will kick it off to Nnamdi first.
Okay. First of all, congrats on the new title.
Thank you. I'd love for you to tell us, since you've joined the company, what you've learned.
What are you most excited about? Maybe we can take it from there.
All right. Well, thanks for having us here today. I appreciate the congratulatory message here. I joined Omnicell about two years ago, and it's been such a great ride. I'll tell you that my background, being in the med tech space for the better part of 25 years and competing in very different therapeutic categories, the one thing I will say that has been enlightening for me joining Omnicell is just how important medication management is to health systems. I know we've put this out there a number of times, that it's hard to get really the clinical and operational objective of a health system right without getting medication management where it needs to be.
When I think about Omnicell, too, I'm excited about where we are because I do feel like we're at the cusp of really transforming how medication management is done with our announcement back in December with our Titan XT platform and OmniSphere. I think we're at the cusp of really designing something that health system customers have been looking for for a long time. A lot of what I've been focused on since I joined the company is really about getting the solution ready for the marketplace, making sure our go-to-market is where it needs to be to take advantage of this moment, and also working with Baird and the rest of the management team to make sure that as we move forward, we're scaling and we're driving profitability across the company as we go forward. Excited to be here. Awesome.
Baird, you joined recently. The company's been in an important transition point right now, moving from stabilizing the core business and coming up to a new refresh cycle. Can you talk about what you've learned and maybe what has sharpened the opportunity going forward here for you?
I'd say the piece that you don't know about a company until you get inside is its level of conviction. I've been really impressed with the conviction of our employee base to solving the evolving set of needs for hospitals and health systems and the pharmacists and nurses that they serve. That has been really encouraging for me to see. It's not just a sticker on a wall at Omnicell. It's what drives our behaviors day in and day out. That's really important as we enter this new refresh cycle. I'd say the second thing I've learned is the opportunities that sit in front of us. You had highlighted heading into the new product cycle and the revenue opportunities that come with a refresh, but also our opportunities to maintain our discipline and to increase our focus on the bottom line.
How can we take this moment of revenue expansion and double down by being more disciplined about our spending decisions and thinking about how we can grow not just revenues over time, but also expand profitability. I'm very impressed with the rigor of the management team, their willingness to think about things through the lens of the investor, and that's been a great place for us to be, and it's a good foundation for us heading into this new cycle.
Awesome. We'll definitely dive into some of those topics shortly here. Nnamdi, I guess just from your perspective, I'd love to understand where do you think the business is maybe stronger than you had expected, and what do you think is the most misunderstood element of the narrative? There's a lot of moving pieces here, but would love to get your thoughts on that.
Well, I'll tell you, just to pick up on something Baird said. When I was evaluating the opportunity to come to Omnicell and having joined the company, something's flying around here. There's a couple of things that stood out to me. Innovation is the way the company started, and it's part of the DNA of who we are as an organization. For example, we have an innovation center in Texas where we bring customers through. Even if it's just to brainstorm and have a conversation about what their challenges are and what they can expect from us to explore to potentially deliver as products down the line, it sort of gives them a window into the fact that we're innovating and we're thinking about their problems in a way that could lead to a product solution or a software solution over time.
That's been a strength of the company. The other thing that really stood out for me as I've joined the company is just how much goodwill we have within the customer base. That aspect of being customer centric is alive and well at Omnicell. I always say this internally at the company that we will do whatever it takes to deliver for a customer, particularly when they're in a bind. That's something that continues to shine through in our focus every day. I'd say the areas where we need to continue to sort of enhance is what I'm calling customer experience. We're doing a lot of work there to couple our technology solution with the best customer experience that we can muster as a company. That's going to be an area that we're going to continue enhancing as we go forward.
With respect to what's been either misunderstood, I think our investors are pretty savvy. At least, I'm spending a lot of time with Baird having those conversations. I don't know that I'd say there's anything that's misunderstood. The thing that I will say that maybe a through line that I see personally in those conversations is the fact that we need to continue reminding investors that a lot of the systems, like automated dispensing cabinets that are standard of care within health systems, these things need to be refreshed on a certain cadence, meaning that you can only sort of defer that investment for so long before you start to create issues, either financially or clinically or operationally. It's more of a timing element of the fact that these things will transact. They need to be refreshed periodically.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
